good morning, everyone. happy new year! and welcome to this special edition of cnn this morning. s this sunday, january 1st, 2023. i got to say it first, boris. i m amara walker. 2023. isn t that crazy, amarah. where does the time go? yeah. thank you so much for joining us on this new year s day. i m boris sanchez. we hope your new year is off to a fantastic start. is it, amara? it s too early to say, but i ll tell you this, i do not set new year s resolutions, because i just disappoint myself. i take it literally day by day. let s survive today, january 1st, and see what the next day brings. i am fully with that sentiment. here s what s ahead for you this hour on cnn this morning. the new year comes with new rules when it comes to filing your taxes. why that could mean a larger paycheck this year. plus, if you ve been to the store lately, there s a good chance that there s an unexpected item in the bagging area. sound familiar? coming up, we ll talk about those
Interviews with political figures and news updates. Interviews with political figures and news updates. Able to sell the shares. They have telephone logs, who called whom and when. It appears they have people helping the government out with the testimony. As mimi said, andrea, its kind of overwhelming evidence thats difficult for federal prosecutors to ignore. And chuck todd, weve not yet seen to my knowledge a tweet from the president or any suggestion that this is witch hunt, mueller related. But this is really separate, this is an investigation that started, there was an Ethics Investigation that we heard about some months back, last year sometime. And so this does not come from the Mueller Operation at all. Right. And thats the thing, it has zero to do this is just bad timing, bad coincidence. And it looks bad, right . Here is yet another person close to the president who seems to be taking advantage of access,
special access, or a pay to play issue. The president s ally, the presi
AUSTIN, Texas, April 05, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
The results of a Phase III trial published this week could soon lead to a new era for the treatment of post-traumatic stress disorder. The study found that a combination of MDMA and psychotherapy was effective at relieving PTSD symptoms when compared to standard therapy. The nonprofit organization funding this research now plans to seek formal approval of MDMA-assisted therapy from the Food and Drug Administration before the end of the year.